Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Conditions
Keywords
Sickle Cell Disease, Sickle Cell Disorders, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell, Haploidentical Transplant, Nonmyeloablative Conditioning, CD4+ T cell, CD4+ T cell-depleted Hematopoietic Cell Transplant, Mixed Chimerism
Brief summary
Blood stem cells can produce red blood cells (which carry oxygen), white blood cells of the immune system (which fight infections) and platelets (which help the blood clot). Patients with sickle cell disease produce abnormal red blood cells. A blood stem cell transplant from a donor is a treatment option for patients with severe sickle cell disease. The donor can be healthy or have the sickle cell trait. The blood stem cell transplant will be given to the patient as an intravenous infusion (IV). The donor blood stem cells will then make normal red blood cells - as well as other types of blood cells - in the patient. When blood cells from two people co-exist in the patient, this is called mixed chimerism. Most children are successfully treated with blood stem cells from a sibling (brother/sister) who completely shares their tissue type (full-matched donor). However, transplant is not an option for patients who (1) have serious medical problems, and/or (2) do not have a full-matched donor. Most patients will have a relative who shares half of their tissue type (e.g. parent, child, and brother/sister) and can be a donor (half-matched or haploidentical donor). Adult patients with severe sickle cell disease were successfully treated with a half-matched transplant in a clinical study. Researchers would like to make half-matched transplant an option for more patients by (1) improving transplant success and (2) reducing transplanted-related complications. This research transplant is being tested in this Pilot study for the first time. It is different from a standard transplant because: 1. Half-matched related donors will be used, and 2. A new combination of drugs (chemotherapy) that does not completely wipe out the bone marrow cells (non-myeloablative treatment) will be used to prepare the patient for transplant, and 3. Most of the donor CD4+ T cells (a type of immune cells) will be removed (depleted) before giving the blood stem cell transplant to the patient to improve transplant outcomes. It is hoped that the research transplant: 1. Will reverse sickle cell disease and improve patient quality of life, 2. Will reduce side effects and help the patient recover faster from the transplant, 3. Help the patient keep the transplant longer and 4. Reduce serious transplant-related complications.
Detailed description
This is a pilot study to determine the safety and feasibility of the COH-MC-17 regimen and ability of the regimen to induce a mixed chimeric status in severe sickle cell disease patients (hemoglobin SS or S-βº Thalassemia). The COH-MC-17 regimen consists of a non-myeloablative regimen (cyclophosphamide, pentostatin and rabbit-anti-thymocyte globulin (ATG)) followed by a CD4+ T-cell-depleted haploidentical hematopoietic cell transplant (HaploHCT).
Interventions
DRUGCyclophosphamide
Orally daily
DRUGPentostatin
Intravenous
Intravenous
DRUGTacrolimus
Initially IV. If patient tolerates, convert to oral.
DRUGMycophenolate mofetil
IV or oral
BIOLOGICALCD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Infusion
Sponsors
City of Hope Medical Center
California Institute for Regenerative Medicine (CIRM)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
Inclusion: 1. Confirmed diagnosis of hemoglobin SS or S-βº Thalassemia sickle cell disease 2. Severe disease status as defined by presence of one or more of the following: 1. Clinically significant neurologic event (stroke) or any neurological deficit lasting \> 24 hours; or increased transcranial Doppler velocity (\>200 m/s). A stroke is defined as a sudden neurologic change lasting more than 24 hours that is accompanied by cerebral magnetic resonance imaging (MRI) changes. 2. History of ≥ 1 episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea). 3. History of ≥ 2 severe vaso-occlusive pain crises (VOC) per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea). A severe VOC is defined as an episode of pain lasting more than 2 hours severe enough to require care at a medical facility. Note that priapism that lasts more than 2 hours and requires care at a medical facility is also considered a VOC. 4. Osteonecrosis of ≥ 2 joints despite the institution of supportive care measures. 5. Prior treatment with regular RBC transfusion therapy, defined as receiving ≥ 8 transfusions per year for \> 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome) 3. No HLA matched sibling or 10/10 matched unrelated donor 4. Related donor who: 1. Is genotypically haploidentical on HLA-A, B, C and DRB1 loci AND 2. Meets institutional criteria 5. Failed prior hydroxyurea therapy or have intolerance to hydroxyurea 6. Meets protocol specified organ function criteria 7. Women of childbearing potential or sexually active male: Agreement to use adequate contraception prior to study entry and 6 months post-transplant.
Exclusion criteria
1. Prior stem cell transplant 2. Prior bone marrow transplant 3. Concurrent other investigational agents, chemotherapy, biological therapy or radiation therapy 4. Planned use of moderate and strong CYP3A4 inhibitors 5. Active infection 6. Major surgery within the last 30 days 7. Clinically significant liver fibrosis or cirrhosis if on chronic transfusion therapy \> 6 months 8. Active malignancy (other than non-melanoma skin cancers) 9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen. 10. Women of childbearing potential: pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mixed Chimerism defined as 30-90% donor cells | Day +60 post-transplant |
| Feasibility of producing an infusion ready CD4+ T-cell-depleted hematopoietic product | From apheresis to Day 0 |
| Toxicity per NCI-Common Terminology Criteria for Adverse Events version 4.0 | Day -22 to 2 years post-transplant |
| Unacceptable Toxicity at least possibly related to COH-MC-17 | Day -22 to Day +60 post-transplant |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Relapse | Up to 2 years post-transplant | — |
| Persistent post-immunosuppressant mixed chimerism | Up to 2 years post-transplant | Between 5% and 95% donor chimerism at two years post- transplant, at least 6 months post- immunosuppressant |
| Adverse events of Grade 3 or higher | Up to 2 years post-transplant | — |
| Neutrophil count ≥ 500/mm3, time to recovery | Up to 2 years post-transplant | — |
| Platelet count ≥ 20,000/mm3, time to recovery | Up to 2 years post-transplant | — |
| Marrow failure | Up to 2 years post-transplant | — |
| Sickle cell disease related complications | Up to 2 years post-transplant | — |
| Non-relapse mortality | Up to 2 years post-transplant | — |
| Acute Graft versus Host Disease per 1994 Keystone Consensus Criteria | Day + 100 post-transplant | — |
| Chronic Graft versus Host Disease per 2014 National Institutes of Health Consensus Criteria | Day+ 180, + 1 year and +2 years post-transplant | — |
| Overall Survival | Up to 2 years post-transplant | — |
| Disease-Free Survival | Up to 2 years post-transplant | — |
| Secondary donor graft failure: Defined as < 5% donor chimerism beyond Day +30 in patients with prior documentation of ≥ 5% donor cells by Day +30 | > Day + 30 up to 2 years post-transplant | — |
| Donor chimerism in blood | Day +30, Day +60, Day +100, Day+180, and +1 yr, +1.5 yr, +2yr post-transplant | — |
| Donor chimerism in bone marrow | Day + 100, Day + 180 and + 1 yr post-transplant | — |
| Persistent immunosuppressant -dependent mixed chimerism | +2 years post-transplant | Between 5% and 95% donor chimerism at two years post- transplant and on immunosuppressant |
| Percent HbS levels | Baseline, and then Day + 30, Day + 100, Day + 180, +1 yr, +1.5, +2yr post-transplant | — |
| Complete chimerism: >95% donor chimerism | +2 years post-transplant | — |
| Primary donor graft failure: Defined as < 5% donor chimerism by Day + 30 post- transplant | Day +30 post-transplant | — |
| Event-Free Survival | Up to 2 years post-transplant | — |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJoseph Rosenthal, MD
City of Hope Medical Center
Outcome results
None listed